Benjamin Vipler/LinkedIn
Sep 24, 2026, 06:33
Benjamin Vipler: Optimal Oral Anticoagulation Choice in Atrial Fibrillation and Advanced CKD
Benjamin Vipler, Associate Professor of Medicine at University of Colorado School of Medicine, shared a post on LinkedIn about a recent article by Qiaoxi Chen et al, published in JAMA Network Open, adding:
“These findings suggest that among patients with atrial fibrillation and advanced chronic kidney disease not receiving dialysis, apixaban may be the preferred oral anticoagulant when anticoagulation is considered.”
Title: Oral Anticoagulants in Patients With Atrial Fibrillation and Advanced CKD Not Requiring Dialysis
Authors: Qiaoxi Chen, Daniel E. Singer, Edouard L. Fu, Chun-Ting Yang, Kevin Pritchard, Rishi J. Desai, Kueiyu Joshua Lin
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 24, 2026, 06:08Christopher Salerno: AI-Powered At-Home Anemia Screening Advances Telehealth Access
-
Sep 24, 2026, 05:38Aya Qattan: When a Normal CBC Does Not Mean Normal Iron Status
-
Sep 24, 2026, 05:11Mastering Warm Autoimmune Hemolytic Anemia Diagnosis and Practice – ASH Education
-
Sep 23, 2026, 16:04Monia Ezzalfani: Advancing Patient-Centered Care in Hemophilia A and B
-
Sep 23, 2026, 15:49Bilge Başak: How Activated PRP Modulates Osteoarthritic Chondrocyte Function
-
Sep 23, 2026, 14:50Mbonjo Bitsie Dora: Strengthening Sickle Cell Care Through Education, Awareness and Innovation
-
Sep 23, 2026, 13:58The New B12 Diagnostic Algorithm: From Serum Cobalamin to Functional Deficiency
-
Sep 23, 2026, 13:56Noha Soror: Preparing for Hematology and Medical Oncology Board Certification
-
Sep 23, 2026, 13:46Ugochi Ogu: What Can Platelet Proteomics Reveal about Pain and Neurocognitive Vulnerability in Sickle Cell Disease?